• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Nephrology
  • Neurology
  • Pulmonology

Top 6 Afib Studies in 2017: Part II

Slideshow

A topline review of 3 more of the top 6 studies of 2017 in afib includes the death of digoxin, go and no-go foods, and afib and ESRD.   

Related Videos
Related Content
Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation More Prevalent in US Than Previously Estimated: Daily Dose

Sydney Jennings
September 26th 2024
Article

Your daily dose of the clinical news you may have missed.

Site Logo

Women and Heart Disease: Incidence, Prevalence, Progress, and the Future

C Noel Bairey Merz, MD;Payal Kohli, MD
April 6th 2013
Podcast

Female CV mortality lags behind male mortality; lifetime risk assessment, not 10-year risk, is a better estimation tool for women

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose / image credit: ©New Africa/AdobeStock

Atrial Fibrillation May be More Common in Younger Adults than Previously Thought: Daily Dose

Sydney Jennings
May 2nd 2024
Article

Your daily dose of the clinical news you may have missed.

The Great Beta-Blocker Debate: The Pros and Cons

The Great Beta-Blocker Debate: The Pros and Cons

Gregory W. Rutecki, MD;Bradley Wright, PharmD
December 12th 2012
Podcast

Newly diagnosed hypertension in a patient whose blood pressure is 152/94 mm Hg. What agents will you consider for this patient? Beta-blockers? Think again.

/ image credit internal bleeding ©Artur/stock.adobe.com

Concomitant SSRI and DOAC Use Increases Risk of Major Bleeding, Including ICH: New Findings

Grace Halsey
March 25th 2024
Article

Overall, a 33% increased risk of major bleeding was seen, with risk highest during the first 30 days of concomitant use and persistent, but lower, after 6 months.

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose / image credit: ©New Africa/AdobeStock

Apixaban and Aspirin Equal in Preventing Stroke Recurrence in Cardiopathy: Daily Dose

Sydney Jennings
February 19th 2024
Article

Your daily dose of the clinical news you may have missed.

© 2025 MJH Life Sciences

All rights reserved.